A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
oleh: Wu-tong Ju, Rong-hui Xia, Dong-wang Zhu, Sheng-jin Dou, Guo-pei Zhu, Min-jun Dong, Li-zhen Wang, Qi Sun, Tong-chao Zhao, Zhi-hang Zhou, Si-yuan Liang, Ying-ying Huang, Yong Tang, Si-cheng Wu, Jing Xia, Shi-qing Chen, Yue-zong Bai, Jiang Li, Qi Zhu, Lai-ping Zhong
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-09-01 |
Deskripsi
In patients with locally advanced resectable oral squamous cell carcinoma (OSCC), the risk of recurrence and metastasis following treatment is high. Here, a phase I clinical trial reports safety and pathological response of neoadjuvant camrelizumab and apatinib in patients with locally advanced resectable OSCC.